Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

Patent metadata

Field	Value
Publication number	US-10040826-B2
Application number	US-201214130338-A
Country	US
Kind code	B2
Filing date	Jul 5, 2012
Priority date	Jul 5, 2011
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.

First claim

What is claimed is:

1. A recombinant protein comprising an HIV-1 envelope (Env) gp120 or gp140, wherein the original 4 to 25 consecutive amino acids of the N-terminus are deleted, wherein the deleted consecutive amino acids are located immediately after the envelope signal peptide and wherein an N-terminal Herpes Simplex gD tag is not substituted for amino acids of the N-terminus.

2. The recombinant protein according to claim 1 wherein 5 to 11 consecutive amino acids of the N-terminus are deleted.

3. The recombinant protein according to claim 1 wherein eleven (11) consecutive amino acids of the N-terminus are deleted.

4. The recombinant protein of claim 1 , wherein seven (7) consecutive amino acids of the N-terminus are deleted.

5. The recombinant protein according to claim 1 wherein said HIV-1 Env is gp120.

6. The recombinant protein according to claim 5 wherein said HIV-1 Env is A244, 1086.C, 089.C, 63521.B, CONS or 6240. B.

7. The recombinant protein according to claim 5 wherein said HIV-1 Env is 040.B or A1C recombinant Env 707-01-069-2.

8. The recombinant protein of claim 3 , wherein the HIV-1 Env is 63521.B delta 11.

9. The recombinant protein of claim 3 , wherein the HIV-1 Env is A244 delta 11.

10. The recombinant protein of claim 3 wherein the HIV-1 Env is 6240.B delta 11.

11. The recombinant protein of claim 3 wherein the HIV-1 Env is MCON-S delta 11.

12. The recombinant protein of claim 3 wherein the HIV-1 Env is 089.0 delta 11.

13. The recombinant protein of claim 4 , wherein the HIV-1 Env is 1086.0 delta 7.

14. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 2.

15. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 4.

16. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 6.

17. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 8.

18. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 10.

19. The recombinant protein according to claim 5 wherein said HIV-1 Env comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 12.

20. A composition comprising said recombinant protein according to claim 1 and a carrier.

21. A composition comprising said recombinant protein according to claim 2 and a carrier.

22. A composition comprising said recombinant protein according to claim 3 and a carrier.

23. A composition comprising said recombinant protein according to claim 4 and a carrier.

24. A composition comprising said recombinant protein according to claim 5 and a carrier.

25. A composition comprising said recombinant protein according to claim 6 and a carrier.

26. A composition comprising said recombinant protein according to claim 8 and a carrier.

27. A composition comprising said recombinant protein according to claim 9 and a carrier.

28. A composition comprising said recombinant protein according to claim 10 and a carrier.

29. A composition comprising said recombinant protein according to claim 11 and a carrier.

30. A composition comprising said recombinant protein according to claim 12 and a carrier.

31. A composition comprising said recombinant protein according to claim 13 and a carrier.

32. A composition comprising said recombinant protein according to claim 14 and a carrier.

33. A composition comprising said recombinant protein according to claim 15 and a carrier.

34. A composition comprising said recombinant protein according to claim 16 and a carrier.

35. A composition comprising said recombinant protein according to claim 17 and a carrier.

36. A composition comprising said recombinant protein according to claim 18 and a carrier.

37. A composition comprising said recombinant protein according to claim 19 and a carrier.

38. An immunogenic composition comprising a recombinant protein comprising an HIV-1 Env gp120 and an adjuvant, wherein the original 4 to 25 consecutive amino acids of the N-terminus of the HIV-1 Env gp120 are deleted, wherein the deleted consecutive amino acids are located immediately after the envelope signal peptide and wherein an N-terminal Herpes Simplex gD tag is not substituted for amino acids of the N-terminus of gp120.

39. The composition of claim 38 , wherein 5 to 11 consecutive amino acids of the N-terminus of the HIV-1 Env gp120 are deleted.

40. The composition of claim 38 , wherein eleven (11) consecutive amino acids of the N-terminus of the HIV-1 Env gp120 are deleted.

41. The composition of claim 38 , wherein seven (7) consecutive amino acids of the N-terminus of the HIV-1 Env gp120 are deleted.

42. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 2.

43. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 4.

44. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 6.

45. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 8.

46. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 10.

47. The immunogenic composition of claim 38 , wherein the recombinant HIV-1 protein comprises the consecutive amino acids immediately after the signal peptide in SEQ ID NO. 12.

48. A method of inducing an immune response in a subject comprising administering to the subject the immunogenic composition of claim 38 in an amount sufficient to effect the induction.

49. The method of claim 48 , wherein 5 to 11 consecutive amino acids of the N-terminus of the recombinant HIV-1 Env gp120 comprised in the immunogenic composition are deleted.

50. The method of claim 48 , wherein eleven (11) consecutive amino acids of the N-terminus of the recombinant HIV-1 Env gp120 comprised in the immunogenic composition are deleted.

51. The method of claim 48 , wherein seven (7) consecutive amino acids of the N-terminus of the recombinant HIV-1 Env gp120 comprised in the immunogenic composition are deleted.

52. The method of claim 48 , wherein the recombinant HIV-1 Env gp120 comprised in the immunogenic composition protein compr

Assignees

• Kim Jerome
• Harrison Stephen
• Haynes Barton F
• Tomaras Georgia D
• Michael Nelson
• Univ Duke
• Us Army
• Childrens Medical Center

Inventors

• Kim Jerome
• Harrison Stephen
• Haynes Barton F
• Tomaras Georgia D
• Michael Nelson

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K14/162

  env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title